Pulmonx Corporation (LUNG) News
Follow Pulmonx Corporation (LUNG) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
LUNG Reports Fiscal Q3 Net Loss
Net profit attributable to shareholders was -3213万美元, up 26.27% year over year; basic EPS was -0.76美元.
EQUITY | Nov 04, 2026, 11:19 AM UTC
M
Pulmonx Reports Third-Quarter 2026 Revenue of $22.84M
Revenue rose 6.2% year over year. Net loss narrowed to $8.39 million, and diluted loss per share improved to $0.19 from $0.34.
EQUITY | Nov 03, 2026, 09:42 PM UTC
M
Pulmonx Shares Rise 13.64% to $2.25 in Extended Trading
Pulmonx shares rose 13.64% to $2.25 in extended trading following results and outlook.
EQUITY | Oct 27, 2026, 08:23 PM UTC
M
Pulmonx Q3 Net Loss Narrows 40% to $8.39 Million
Pulmonx’s third-quarter 2026 net loss narrowed 40% to $8.39 million.
EQUITY | Oct 27, 2026, 08:17 PM UTC
M
Pulmonx Q3 Revenue Beats Analyst Estimates on U.S. Sales Growth
EQUITY | Oct 27, 2026, 08:17 PM UTC
M
Pulmonx Reports Lower Q3 2026 Net Loss and Higher Revenue
Pulmonx reported a lower net loss and higher revenue in the third quarter of 2026.
EQUITY | Oct 27, 2026, 08:12 PM UTC
M
Pulmonx Reports Third-Quarter 2026 Financial Results
EQUITY | Oct 27, 2026, 08:08 PM UTC
M
Pulmonx to report third-quarter 2026 results October 27
EQUITY | Oct 13, 2026, 08:05 PM UTC
L
Pulmonx announces inducement equity grants under Nasdaq Rule 5635(c)(4)
Pulmonx (LUNG) said it granted equity awards on September 1, 2026 under its 2025 inducement grants program tied to Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Pulmonx announces inducement grants under Nasdaq Rule 5635(c)(4)
Pulmonx Corporation announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:05 PM UTC
L
Pulmonx to participate in upcoming investor conferences
Pulmonx says it will participate in upcoming investor conferences.
EQUITY | Aug 27, 2026, 08:07 PM UTC
L
LUNG - Pulmonx to Participate in Upcoming Investor Conferences
LUNG - Pulmonx to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 08:05 PM UTC
H
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%
PRCH +20%, CORT +18.3%, BOOM +17.3%, FORM +16.4%, SBUX +10.2%, FTNT +9.4%, BHE +9.3%, LUNG +8.8%, LRCX +7.6%, CMG +7.1%, GKOS +7%, GFL +5.7%, RGR 4.8%, MOD +3.9%, ICLR +3.8%, ST +3.6%, MAX +2.6%, EQIX +2.4% after results
EARNINGS | Jul 29, 2026, 08:27 PM UTC
L
Pulmonx Affirms FY2026 Sales Guidance of $90.000M-$92.000M vs $90.832M Est
Pulmonx (NASDAQ: LUNG ) affirms FY2026 sales outlook from $90.000 million-$92.000 million to $90.000 million-$92.000 million vs $90.832 million estimate.
EARNINGS | Jul 29, 2026, 08:15 PM UTC
L
LUNG Pulmonx RESULTS: Q2, Q2 REV $22.756M vs. EST $22.4M, Q2 gross profit $17.742M, Q2 Net Income $-10.08M, Q2 Income from operations $-9.05
LUNG Pulmonx RESULTS: Q2, Q2 REV $22.756M vs. EST $22.4M, Q2 gross profit $17.742M, Q2 Net Income $-10.08M, Q2 Income from operations $-9.057M, Q2 pretax profit $-9.947M, Q2 EPS $-0.24, Pulmonx Earnings Notes:, Outlook F
EARNINGS | Jul 29, 2026, 08:10 PM UTC
L
LUNG - Pulmonx Reports Second Quarter 2026 Financial Results
LUNG - Pulmonx Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 08:07 PM UTC
H
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - HOOD, VTR, MKL, HLI, MGM, ARMN, NFG, MC, AM, QTWO
serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - HOOD, VTR, MKL, HLI, MGM, ARMN, NFG, MC, AM, QTWO, CVI, TDOC, ALKT, MGRC, BBNX, PMT, MAX, LXU, CLB, MDXG, CLMB, FPI, UAN, MFIN, L
EARNINGS | Jul 29, 2026, 05:04 PM UTC